Quandary Remains In Creating Abuse-Resistant Opioid Painkillers
Executive Summary
FDA's advisory committees honed in on the inherent paradox in the regulation of abuse-resistant opioid painkillers - that it is impossible to fully prove an abuse-deterrent effect without approving a product and seeing how it works on the market - at the April 22 review of King/Acura's Acurox
You may also be interested in...
Alkermes' Vivitrol For Opioid Dependence Could Be Dealt Wild Card At Advisory Committee
Expert panels have recently shown they may think differently from FDA on the subject of opioids..
FDA Finalizing Opioid REMS Proposal, Sets Joint Advisory Committee Meeting For July
FDA wants to gather feedback from advisors and from the public on the classwide REMS for opioid analgesics, and judging from the stakeholder meetings the agency has held so far, it will get an earful.
King Aims To File New Acurox NDA In Early 2011
King Pharmaceuticals expects to file a new drug application in early 2011 for its pain drug Acurox, excluding niacin as a potential abuse deterrent, execs told investors during a first quarter earnings call May 5